Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study by Jing Yang, Jing Zhang, Xinyu Wan, Jiaoyang Cai, Jiaoyang Cai, Tianyi Wang, Xiaomin Yang, Wenjie Li, Lixia Ding, Lili Song, Yan Miao, Xiang Wang, Yani Ma, Chengjuan Luo, Jingyan Tang, Longjun Gu, Jing Chen, Jun Lu, Yanjing Tang, Benshang Li

“…IntroductionCorticosteroids are used for toxicity management, raising concerns about whether they may affect the anti-leukemic effects of chimeric antigen receptor (CAR)-T cells.Methods and resultsIn this study, we retrospectively analyzed patients (fined two subgroups based on disease burden. …”
Get full text

Synthesis and characterization of zinc oxide nanoparticles-carbon composite derived from pineapple peel wastes for adsorption of methylene blue from solution and photocatalytic act... by Salsa Putri Alzura, Vienna Saraswaty, Safri Ishmayana, Yudha Prawira Budiman, Diana Rakhmawaty Eddy, Evyka Setya Aji, Diah Ratnaningrum, Een Sri Endah, Hanny Meirinawati, Henry Setiyanto

“…Synthetic dye effluent poses substantial environmental issues due to its toxicity. In this work, a biosorbent derived from pineapple peels and modified with zinc oxide nanoparticles namely ZnONPs/PPWB, was prepared for the removal of cationic dyes, specifically methylene blue (MB), from aqueous solution. …”
Get full text

Vertical bacterial variability in oxidation ponds in the tropical zone by C. Tudsanaton, T. Pattamapitoon, O. Phewnil, W. Wararam, K. Chunkao, P. Maskulrath, M. Srichomphu

“…Anaerobic bacteria can be found in wastewater and used in treatment systems due to their protective mechanisms against oxygen toxicity and self-repair mechanisms. The knowledge gained from this study can be used as a reference in future works on natural wastewater treatment systems.…”
Get full text

Mitigation of polycyclic aromatic hydrocarbons (PAHs) in roasted beef patties by cold plasma treatment and products quality evaluation by Yuke Hou, Yangjian Hu, Min Li, Jiahui Nong, Fengyuan Xie, Yuhan Fan, Jianhao Zhang, Xianming Zeng, Minyi Han, Xinglian Xu, Xia Wang

“…In conclusion, CP treatment degraded PAHs through stepwise ring-opening oxidation in 2 reported pathways, the toxicity of PAHs contaminated products was alleviated after CP treatment.…”
Get full text

Evaluation of in-vitro and in-silico antidiabetic potential, glucose metabolism, antioxidant, cytotoxicity and phytochemical content of Ipomoea bolusiana Schinz and Ipomoea crassip... by Garland Kgosi More, Nolitha Nkobole, Charmy Twala, Sechaba Machedi, Tebogo Amos Moswetsa, Ramakwala Christinah Chokwe

“…However, the extracts were less toxic to the cells as they showed IC50 values > 20 µg/mL. …”
Get full text

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results... by Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwé, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frédéric Amant, Katrien Vandecasteele, Hannelore G. Denys

“…In conclusion, PRIMMO did not meet its primary objective in both cohorts; pembrolizumab, radiotherapy, and an IDC had modest but durable antitumor activity with acceptable but not negligible toxicity. Trial registration ClinicalTrials.gov (identifier NCT03192059) and EudraCT Registry (number 2016-001569-97).…”
Get full text

Evaluation of gamma rays shielding properties of bismuth tungstate with different morphologies by Qiang Yan, Yong Li, Guowei Wang, Zhengxin Wu, Haitao Zhang, Chuyuan Mao, Zhiqiang Long, Guoqing Liu

“…The results of this study provide a reference for the development of new flexible radiation shielding materials with non-toxicity, light weight and high efficiency.…”
Get full text

Anti-Inflammatory and Healing Activity of the Hydroalcoholic Fruit Extract of Solanum diploconos (Mart.) Bohs by Larissa Benvenutti, Roberta Nunes, Ivonilce Venturi, Silvia Aparecida Ramos, Milena Fronza Broering, Fernanda Capitanio Goldoni, Sarah Eskelsen Pavan, Maria Verônica Dávila Pastor, Angela Malheiros, Nara Lins Meira Quintão, Elizabeth Soares Fernandes, José Roberto Santin

“…Additionally, the acute and subacute toxic and genotoxic effects of the extract were evaluated. …”
Get full text

USP14 inhibition by degrasyn induces YAP1 degradation and suppresses the progression of radioresistant esophageal cancer by Fang Yuan, Juan Xu, Lingmei Xuan, Chan Deng, Wei Wang, Rong Yang

“…Animal experiments confirmed the effective role of the DGS and X-ray combined treatment in reducing tumor growth and irradiation tolerance of ESCA in vivo with undetectable toxicity. Importantly, the promotive and malignant biological behaviors of ESCA cells suppressed by the DGS/X-ray combination treatment were almost eliminated by USP14 overexpression, along with the abolished DNA damage process. …”
Get full text

Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study by Zhongli Hu, Zinan Feng, Shiqi Liu, Hai He, Ying Dong, Zhiping Fan, Yiqing Li, Fen Huang, Na Xu, Can Liu, Yunxin Zeng, Ping Zhu, Ren Lin, Hua Jin, Xiong Zhang, Ruijuan Sun, Qifa Liu, Li Xuan

“…There was no difference in regimen-related toxicity, engraftment, or graft-versus-host disease between the intensified and standard groups. …”
Get full text

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) by Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, Yun Fan, Guowu Wu, Shundong Cang, Yi Yang, Nong Yang, Rui Ma, Gaowa Jin, Ximing Xu, Anwen Liu, Shubin Tang, Ying Cheng, Yan Yu, Chong-Rui Xu, Qing Zhou, Yi-Long Wu

“…Conclusion Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression. …”
Get full text

Establishment of a Novel Model for Anticancer Drug Resistance in Three-Dimensional Primary Culture of Tumor Microenvironment by Tatsuya Usui, Masashi Sakurai, Shuhei Enjoji, Hideyoshi Kawasaki, Koji Umata, Takashi Ohama, Nobuyuki Fujiwara, Ryotaro Yabe, Shunya Tsuji, Hideyuki Yamawaki, Shoichi Hazama, Hiroko Takenouchi, Masao Nakajima, Ryouichi Tsunedomi, Nobuaki Suzuki, Hiroaki Nagano, Koichi Sato

“…Tumor organoids were more resistant to toxicity of 5-fluorouracil and Irinotecan than colorectal cancer cell lines, SW480, SW620, and HCT116. …”
Get full text

Relative bioavailability of selenium yeast, selenomethionine, hydroxyl-selenomethionine and nano-selenium for broilers by Guoqing Liu, Guoqing Liu, Sumei Cao, Sumei Cao, Liang Huang, Xuanxu Lin, Zheng Sun, Gang Lin, Liyang Zhang, Lin Lu, Xugang Luo, Xiudong Liao

“…Development and application of new forms of Se sources with lower toxicity and higher bioavailability has been attracting more attention. …”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…Of the 140 patients enrolled, 138 were eligible, 138 were evaluable for toxicity and 128 (91%) were evaluable for response. …”
Get full text

Repurposing the prostaglandin analogue treprostinil and the calcium-sensing receptor modulator cinacalcet to revive cord blood as an alternate source of hematopoietic stem and prog... by Michaela Prchal-Murphy, Julia Zehenter, Marlene Fischer, Anita Pirabe, Madeleine Themanns, Behnaz Afrashteh, Eva Maria Putz, Karoline Kollmann, José Basílio, José Basílio, Manuel Salzmann, Wolfgang Strohmaier, Günther Krumpl, Alex Farr, Veronika Sexl, Michael Freissmuth, Eva Zebedin-Brandl

“…ObjectiveThe expanding field of hematopoietic cell transplantation (HCT) for non-malignant diseases, including those amenable to gene therapy or gene editing, faces challenges due to limited donor availability and the toxicity associated with cell collection methods. Umbilical cord blood (CB) represents a readily accessible source of hematopoietic stem and progenitor cells (HSPCs); however, the cell dose obtainable from a single cord blood unit is frequently insufficient. …”
Get full text

Optimal timing of organs-at-risk-sparing adaptive radiation therapy for head-and-neck cancer under re-planning resource constraints by Fatemeh Nosrat, Cem Dede, Lucas B. McCullum, Raul Garcia, Abdallah S.R. Mohamed, Jacob G. Scott, James E. Bates, Brigid A. McDonald, Kareem A. Wahid, Mohamed A. Naser, Renjie He, Aysenur Karagoz, Amy C. Moreno, Lisanne V. van Dijk, Kristy K. Brock, Jolien Heukelom, Seyedmohammadhossein Hosseinian, Mehdi Hemmati, Andrew J. Schaefer, Clifton D. Fuller

“…Materials and methods: A novel Markov decision process (MDP) model was developed to determine optimal timing of re-planning based on the patient’s expected toxicity, characterized by normal tissue complication probability (NTCP), for four toxicities. …”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

“…Compared with the chemotherapy group, CP improved OS (HR: 0.84, 95% CI: 0.75-0.94, p<0.05) but not PFS (HR: 0.94, 95%CI: 0.73-1.20, p = 0.63) or ORR (OR: 1.16, 95% CI: 0.79-1.71, p = 0.45). In terms of toxicity, CP had slightly fewer any AEs compared to chemotherapy (RR: 0.94, 95% CI: 0.91-0.97; p<0.05). …”
Get full text

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III... by Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson

“…Patients randomised to the standard, reactive arm will commence at the full dose followed by toxicity dependent reactive modifications. Patients randomised to the adaptive arm will commence at a dose level determined by their International Myeloma Working Group frailty score. …”
Get full text

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study by Chenyu Mao, Anwen Xiong, Jiong Qian, Wenxiang Wang, Ying Liu, Tao Zhang, Zhihai Wu, Haiqing Ni, Jia Lu, Sixiang Long, Li Zhao, Yuling Chen, Caicun Zhou, Nong Xu

“…In phase Ib combination dose escalation (n = 45), TRAEs occurred in 75.6% patients and grade ≥ 3 TRAEs occurred in 22.2% patients. No dose-limiting toxicity (DLT) was observed. The most common TRAE was anemia (17.9%, including 3.6% ≥ G3) in phase Ia dose escalation of IBI110 monotherapy (n = 28), aspartate aminotransferase increased (28.9%, all G1-G2) in phase Ib dose escalation of IBI110 plus sintilimab (n = 45), anemia (70.0%, all G1-G2) in phase Ib dose expansion in sqNSCLC (n = 20), and neutrophil count decreased (64.7%, including 17.6%≥ G3) in phase Ib dose expansion in GC (n = 17). …”
Get full text

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma by Leonard D’Amico, Martin Cheever, Steven P Fling, Anna Wright, Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Thomas S Uldrick, Robert Yarchoan, Judith C Kaiser, Angela Shaulov Kask, Manoj P Menon, Paul Couey, Eli Burnham, Allysson Angeldekao, Byung Ha Lee, Li-Lian Kwok, Chia-Ching Jackie Wang

“…Injection site reaction was a dose-limiting toxicity in one participant at DL1. The overall KS objective response rate to NT-I7 was 42.9% (95% CI 9.9%, 81.6%) and all three responders were PWH. …”
Get full text